Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ziba Naseri

Physician Assistant Hermitage, PA Physician Assistant

NPI 1396140380 CMS profile 10852363

2500 Highland Rd Ste 101, Hermitage, PA 16148

Open in the dashboard

General payments

$21,751

1,167 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ziba Naseri of Hermitage, PA is reported in the CMS Open Payments database as having received $21,751 across 1,167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,079 188
2024 General $4,853 250
2023 General $4,874 240
2022 General $3,668 225
2021 General $4,278 264

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziba Naseri
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ziba Naseri were reported at $4,079. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ziba Naseri Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,278 $132 $37–$438 $132
2022 $3,668 $155 $48–$522 $149
2023 $4,874 $167 $52–$557 $160
2024 $4,853 $178 $55–$600 $164
2025 $4,079 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $4,770 246 payments
  2. AbbVie, Inc. $3,552 237 payments
  3. Amgen Inc. $3,474 158 payments
  4. UCB, Inc. $2,436 124 payments
  5. Pfizer Inc. $1,179 86 payments
  6. Novartis Pharmaceuticals Corporation $1,004 63 payments
  7. Lilly USA, LLC $807 46 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $674 27 payments
  9. GlaxoSmithKline, LLC. $649 33 payments
  10. AstraZeneca Pharmaceuticals LP $640 33 payments
  11. Other $2,565 114 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,826 1,157 payments
  2. Education $475 9 payments
  3. Consulting Fee $450 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $4,781 216 payments
  2. RINVOQ $2,711 178 payments
  3. SIMPONI ARIA $2,176 138 payments
  4. Cimzia $1,761 88 payments
  5. Otezla $1,435 61 payments
  6. Enbrel Inflammation $1,366 59 payments
  7. Enbrel Inflammation $1,072 52 payments
  8. STELARA $924 36 payments
  9. XELJANZ $811 66 payments
  10. TALTZ $694 44 payments
  11. Other $9,739 557 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

3,179

Median for Physician Assistant: 241

Drug cost

$710,314

Median for Physician Assistant: $4,110

Branded share of claims

21.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orencia Abatacept/Maltose Brand 62 $274,889
Humira(Cf) Pen Adalimumab Brand 33 $222,416
Enbrel Sureclick Etanercept Brand 17 $139,583
Prolia Denosumab Brand 12 $19,562
Hydroxychloroquine Sulfate Generic 639 $18,208
Methotrexate Methotrexate Sodium Brand 553 $9,785
Duloxetine Hcl Generic 433 $7,138
Leflunomide Generic 68 $3,891
Gabapentin Generic 244 $3,616
Prednisone Generic 441 $3,006

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$83,709

Of which drugs: $76,083

Medicare patients

83

Average age 73

Services billed

9,296

52 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Osteoporosis 37%
Diabetes 36%
Chronic kidney disease 30%
Ischemic heart disease 24%
Depression 20%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 16 1,150 $38,624
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 14 6,400 $22,741
Injection, denosumab, 1 mg J0897 Office 11 660 $12,666

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$868 — —
RINVOQ
$435 — —
Cimzia
$413 — 6,400
Enbrel
$386 17 —
SKYRIZI
$330 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record